Numerai’s Theravance Biopharma TBPH Stock Holding History

Numerai’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,849	Closed	-$671K	–	884
2025 Q4	$671K	Buy	35,849 +7,617	+27%	+$126K	0.08%	337
2025 Q3	$412K	Buy	+28,232	New	+$357K	0.06%	371

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Numerai's TBPH Position: Q1 2026 in Review

Numerai sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 35,849 shares — an estimated $671K sold.

Numerai first reported a position in TBPH in Q3 2025 and held it in 2 quarters. The position peaked at $671K in Q4 2025. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

Numerai reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
Numerai sold 35,849 Theravance Biopharma shares in Q1 2026, an estimated $671K.
Numerai first reported a position in Theravance Biopharma in Q3 2025 and held it in 2 quarters.
Numerai's Theravance Biopharma position peaked at $671K in Q4 2025.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.